These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30552364)

  • 1. miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs.
    Zhang N; Li Y; Zheng Y; Zhang L; Pan Y; Yu J; Yang M
    Lab Invest; 2019 Apr; 99(4):568-576. PubMed ID: 30552364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lei T; Zhang L; Song Y; Wang B; Shen Y; Zhang N; Yang M
    DNA Cell Biol; 2020 Jul; 39(7):1111-1118. PubMed ID: 32343915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop.
    Wu DW; Wang YC; Wang L; Chen CY; Lee H
    Theranostics; 2018; 8(5):1256-1269. PubMed ID: 29507618
    [No Abstract]   [Full Text] [Related]  

  • 7. DACT2 modulated by TFAP2A-mediated allelic transcription promotes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Zhang N; Li Y; Xie M; Song Y; Liu J; Lei T; Shen Y; Yu J; Yang M
    Biochem Pharmacol; 2020 Feb; 172():113772. PubMed ID: 31866302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
    BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogene HSPH1 modulated by the rs2280059 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Li Y; Zhang N; Zhang L; Song Y; Liu J; Yu J; Yang M
    Carcinogenesis; 2020 Sep; 41(9):1195-1202. PubMed ID: 32815538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RNA editing enzyme ADAR modulated by the rs1127317 genetic variant diminishes EGFR-TKIs efficiency in advanced lung adenocarcinoma.
    Hua H; Zeng J; Xing H; He Y; Han L; Zhang N; Yang M
    Life Sci; 2022 May; 296():120408. PubMed ID: 35202641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.
    Li N; Zuo R; He Y; Gong W; Wang Y; Chen L; Luo Y; Zhang C; Liu Z; Chen P; Guo H
    Cell Death Dis; 2024 Aug; 15(8):555. PubMed ID: 39090096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
    Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.
    Yuan J; Li B; Zhang N; Zhu H; Zhou L; Zhang L; Yang M
    Clin Lung Cancer; 2018 Jul; 19(4):e431-e438. PubMed ID: 29580739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
    Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW
    BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
    Ge P; Cao L; Chen X; Jing R; Yue W
    BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.